Acurx Pharmaceuticals, Inc..
ACXP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Acurx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. Their primary focus is on developing oral antibiotics that target Clostridium difficile infection (CDI). Their lead product candidate is ibezapolstat, a novel, orally a...Show More
Better Health for All
0
No evidence available to assess Acurx Pharmaceuticals, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Acurx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing new antibiotics.
1
The provided articles detail its scientific publications, corporate governance, SEC filings, clinical trial results, regulatory designations, and corporate finance activities such as warrant exercises and treasury investments. There is no evidence in the articles to suggest that the company operates as a financial institution, offers lending or deposit services to consumers, or engages in any activities related to financial inclusion or economic opportunity as defined by the KPIs for this value. Therefore, all KPIs are omitted due to a lack of relevant evidence.
Fair Pay & Worker Respect
20
Acurx Pharmaceuticals, Inc. had four full-time employees as of March 17, 2025, and consistently had fewer than 10 employees from 2020 to 2024.
1
None of the company's employees are represented by labor unions or covered by collective bargaining agreements.
2
All employees are full-time, indicating that 0% of the workforce is on temporary, zero-hour, or gig contracts without benefits.
3
The company considers its relationship with its employees to be good and has equity and cash incentive plans to attract, retain, and reward personnel.
4
Executive compensation for 2024 included $1,431,383 for the President and CEO, $1,463,430 for the Executive Chairman, and $907,463 for the Chief Financial Officer.
5
Independent directors receive an annual cash retainer of $40,000, with additional retainers for committee chairs and members.
6
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles that directly address the company's performance against the defined KPIs for Fair Trade & Ethical Sourcing. The articles primarily focus on financial performance, drug development, regulatory compliance (e.g., FDA audits for product quality and manufacturing processes), and internal corporate governance, including a Code of Ethics. Information regarding fair trade certifications, supplier audit frequency for ethical sourcing, forced or child labor incidents, supply chain traceability, remediation speed for supplier violations, ethical clauses in supplier contracts, materials risk, or supplier diversity spend was not explicitly provided.
Honest & Fair Business
-30
The company received Nasdaq non-compliance letters on February 24, 2025, and March 25, 2025, regarding minimum bid price and stockholders' equity requirements, respectively, but no ethics-related fines were reported in the past three years.
1
The Audit Committee is responsible for establishing procedures for confidential, anonymous submission of employee concerns via a whistleblower hotline, with a non-retaliation policy.
2
However, there is no evidence of independent investigation processes for these reports. Five out of seven board members (approximately 71.4%) are identified as independent directors as defined by Nasdaq.
3
The company has adopted a code of conduct and ethics applicable to all employees, including executive officers,
4
and is subject to the United States Foreign Corrupt Practices Act,
5
but details on training frequency or effectiveness metrics are not provided. The company regularly engages a third-party cyber specialist to review its cybersecurity program and ensure system effectiveness,
6
indicating some independent verification of information security risks.
Kind to Animals
-50
The company explicitly uses animal testing, including in vivo animal models, humanized mouse models, germ-free mouse models, and microbiome-humanized mice, as part of its IND-enabling preclinical studies and product testing.
1
No formal policy regarding the reduction or restriction of animal testing is stated.
2
While the company also employs non-animal methods such as Ames test, Mouse Lymphoma Assay, Micronucleus assay, and hERG Assay for early-stage toxicity screens, these are not indicated to cover complex endpoints, and animal models are still extensively used for other preclinical studies.
3
No War, No Weapons
0
No relevant evidence was found in the provided articles to assess Acurx Pharmaceuticals, Inc. (ACXP.US) against the 'No War, No Weapons' ethical value.
1
pertains to AcelRx Pharmaceuticals, Inc. (ACRX), a different company, and explicitly states that no data relevant to ACXP.US or the 'No War, No Weapons' value is present.
2
Planet-Friendly Business
0
No specific, concrete data points related to planet-friendly business metrics, environmental performance, or sustainability initiatives were found in the provided articles for Acurx Pharmaceuticals, Inc. The articles explicitly state a lack of any environmental, social, and governance (ESG) data and that sustainability data is unavailable.
1
Respect for Cultures & Communities
0
No specific, concrete evidence regarding Acurx Pharmaceuticals, Inc.'s respect for cultures and communities, as defined by the provided KPIs, was found in the articles. The articles focused on clinical trial data
1
, internal board diversity
2
, or general DEI initiatives of another company (Ironwood Pharma)
3
, none of which provided quantifiable data for the specified metrics for ACXP.US.
Safe & Smart Tech
0
The company provides regular mandatory security training for employees and contractors, including phishing simulations and annual cybersecurity management and incident training.
1
For authentication security, it employs access controls, firewalls, and intrusion prevention and detection systems.
2
The company conducts vulnerability assessments and utilizes cybersecurity threat intelligence for vulnerability management.
3
Additionally, it monitors emerging data protection laws to ensure regulatory compliance.
4
Zero Waste & Sustainable Products
0
No specific sustainability data, quantitative metrics, or information regarding waste management, product recyclability, packaging sustainability, or any other zero waste and sustainable product initiatives for ACXP.US were found.
1
The provided articles explicitly state that sustainability data is currently not available for the company, and no relevant data could be extracted for any of the specified metrics.
2